American Society of Hirudotherapy

A novel selective inhibitor to thrombin-induced platelet aggregation purified from the leech Whitmania pigra

Research article published in Biochem Biophys Res Commun (2016)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Preclinical (animal)Genomics & ProteomicsSalivary PharmacologyLiu X et al. · Biochem Biophys Res Commun, 2016

Abstract

BACKGROUND/AIM: The dried whole body of the leech Whitmania pigra, a well-known traditional Chinese medicine, has been widely used to treat thrombus diseases for thousands of years. However, its bioactive constituents were reported rarely. The aim of our study was to investigate antithrombotic components of it. METHODS: The antithrombotic peptide was purified using a combination of anion-exchange chromatography, ultrafiltration and reverse-phase HPLC. the sequence of the peptide was determined using MALDI-TOF-MS-MS. Anti-platelet aggregation activity in vitro was evaluated using a turbidimetric method, and antithrombotic effect in vivo was assessed in an arterio-venous shunt thrombosis model in rats. RESULTS: A novel antithrombotic peptide named WP-30, with the sequence VISRTQSNVQAAWGQVGGHAADYSAVAIER, was isolated from the dried whole body of the leech W. pigra. WP-30 selectively inhibited thrombin-induced anti-platelet aggregation in vitro, and potently attenuated thrombus formation in rats in vivo. CONCLUSIONS: Taken together, we found a novel peptide from leech bodies, and this peptide showed antiplatelet aggregation and antithrombotic effects.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAmino Acid SequenceAnimalsChromatography, High Pressure LiquidFibrinolytic AgentsLeechesMedicine, Chinese TraditionalMolecular Sequence DataPeptidesPlatelet AggregationRatsRats, Sprague-DawleySpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationThrombosis

Summary

From the dried body of the leech Whitmania pigra, researchers purified WP-30, a novel peptide that selectively inhibited thrombin-induced platelet aggregation in vitro and attenuated thrombus formation in a rat arteriovenous shunt model.

Why This Matters for Hirudotherapy

This study isolated and characterized a novel antithrombotic peptide, WP-30 (sequence VISRTQSNVQAAWGQVGGHAADYSAVAIER), from the dried whole body of the leech Whitmania pigra, a traditional Chinese medicine used for thrombotic diseases. Purified via anion-exchange chromatography, ultrafiltration, and reverse-phase HPLC, the peptide selectively inhibited thrombin-induced platelet aggregation in vitro and attenuated thrombus formation in a rat arterio-venous shunt model. Findings are preclinical, limited to in-vitro antiplatelet assays and an in-vivo rat thrombosis model; no human data, no hirudotherapy application, and no comparison to other leech species are presented in the abstract.

Citation

Reference (Vancouver style)

Liu X, Wang C, Ding X, Liu X, Li Q, Kong Y. A novel selective inhibitor to thrombin-induced platelet aggregation purified from the leech Whitmania pigra. Biochem Biophys Res Commun. 2016;473(1):349-354. doi:10.1016/j.bbrc.2016.03.117. PMID: 27021679

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.